Prenatal Exposure to Acid-Suppressive Medications and Incident Risk of Inflammatory Bowel Disease in Children - Takeaways - MDSpire

Prenatal Exposure to Acid-Suppressive Medications and Incident Risk of Inflammatory Bowel Disease in Children

  • By

  • Jiyeon Oh

  • Jaeyu Park

  • Hyunjee Kim

  • Hyesu Jo

  • Kyeongmin Lee

  • Yeona Jo

  • Seohyun Hong

  • Sooji Lee

  • Selin Woo

  • Yerin Hwang

  • Jinseok Lee

  • Tae Hyeong Kim

  • Hayeon Lee

  • June 24, 2026

  • 0 min

Share

  • 1

    Prenatal use of acid-suppressive medications, including PPIs and H2RAs, is common among pregnant women experiencing gastroesophageal reflux.

  • 2

    Emerging evidence suggests that prenatal exposure to acid-suppressive drugs may increase the risk of allergic diseases and congenital malformations in children.

  • 3

    The study examines the association between prenatal acid-suppressive medication exposure and the risk of pediatric-onset inflammatory bowel disease (IBD).

  • 4

    A nationwide birth cohort in South Korea, covering nearly 3 million mother-child pairs, was utilized to assess this association.

  • 5

    Prenatal exposure to acid-suppressive medications was defined as having one or more prescriptions during pregnancy, with IBD diagnosed postnatally.

Original Source(s)

Related Content